Kura Oncology Inc

NASDAQ KURA

Data sourced from

and

Daily

Download Data

Kura Oncology Inc Enterprise Value to EBITDA (EV/EBITDA) on June 03, 2024: -6.14

Kura Oncology Inc Enterprise Value to EBITDA (EV/EBITDA) is -6.14 on June 03, 2024, a -74.32% change year over year. The EV/EBITDA ratio compares a company's enterprise value to its EBITDA. It provides insight into the company's valuation relative to its earnings and is commonly used in comparing the relative value of different companies within an industry. A lower ratio suggests a potentially more favorable valuation.

Kura Oncology Inc 52-week high Enterprise Value to EBITDA (EV/EBITDA) is -0.58 on October 23, 2023, which is 90.49% above the current Enterprise Value to EBITDA (EV/EBITDA).
Kura Oncology Inc 52-week low Enterprise Value to EBITDA (EV/EBITDA) is -8.54 on March 08, 2024, which is -39.06% below the current Enterprise Value to EBITDA (EV/EBITDA).
Kura Oncology Inc average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is -3.83.

NASDAQ: KURA

Kura Oncology Inc

CEO	Dr. Troy Edward Wilson J.D., Ph.D.
IPO Date	Sept. 22, 2015
Location	United States
Headquarters	12730 High Bluff Drive, San Diego, CA, United States, 92130
Employees	142
Sector	Healthcare
Industry	Biotechnology

Description

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Key trends